{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T04:47:37Z","timestamp":1788583657143,"version":"build-2803163510"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T00:00:00Z","timestamp":1766793600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000196","name":"Canada Foundation for Innovation","doi-asserted-by":"publisher","award":["45901"],"award-info":[{"award-number":["45901"]}],"id":[{"id":"10.13039\/501100000196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000196","name":"Canada Foundation for Innovation","doi-asserted-by":"publisher","award":["38622"],"award-info":[{"award-number":["38622"]}],"id":[{"id":"10.13039\/501100000196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009326","name":"Cancer Research Society","doi-asserted-by":"publisher","award":["1449872"],"award-info":[{"award-number":["1449872"]}],"id":[{"id":"10.13039\/100009326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009326","name":"Cancer Research Society","doi-asserted-by":"publisher","award":["1051060"],"award-info":[{"award-number":["1051060"]}],"id":[{"id":"10.13039\/100009326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-517664"],"award-info":[{"award-number":["PJT-517664"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Metabolism"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.molmet.2025.102316","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:22:11Z","timestamp":1767745331000},"page":"102316","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Targeting DHODH reveals a metabolic vulnerability in AR-positive and AR-negative prostate cancer cells via pyrimidine synthesis and metabolic crosstalk with the TCA and urea cycles"],"prefix":"10.1016","volume":"104","author":[{"given":"Maxime","family":"Labroy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc-Oliver","family":"Par\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Line","family":"Berthiaume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lissa","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Jobin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Veilleux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Pelletier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Pouliot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Masson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7710-8365","authenticated-orcid":false,"given":"\u00c9tienne","family":"Audet-Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.molmet.2025.102316_bib1","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.molmet.2025.102316_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1589694","article-title":"Editorial: metastatic hormone-sensitive prostate cancer: new therapeutic strategies to improve patient outcome","volume":"15","author":"Chinen","year":"2025","journal-title":"Front Oncol"},{"issue":"Pt B","key":"10.1016\/j.molmet.2025.102316_bib3","article-title":"Impacts of endocrine-disrupting chemicals on prostate function and cancer","volume":"204","author":"Lacouture","year":"2022","journal-title":"Environ Res"},{"issue":"8","key":"10.1016\/j.molmet.2025.102316_bib4","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41585-023-00726-1","article-title":"Preclinical models of prostate cancer - modelling androgen dependency and castration resistance in vitro, ex vivo and in vivo","volume":"20","author":"Germain","year":"2023","journal-title":"Nat Rev Urol"},{"issue":"24","key":"10.1016\/j.molmet.2025.102316_bib5","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2017.77.6880","article-title":"Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study","volume":"36","author":"Aggarwal","year":"2018","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.molmet.2025.102316_bib6","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.euo.2024.12.014","article-title":"Emergence of neuroendocrine tumors in patients treated with androgen receptor pathway inhibitors for metastatic prostate cancer: a systematic review and meta-analysis","volume":"8","author":"S\u00e9guier","year":"2025","journal-title":"Eur Urol Oncol"},{"issue":"6","key":"10.1016\/j.molmet.2025.102316_bib7","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1158\/2159-8290.CD-11-0130","article-title":"Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets","volume":"1","author":"Beltran","year":"2011","journal-title":"Cancer Discov"},{"issue":"3","key":"10.1016\/j.molmet.2025.102316_bib8","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.cmet.2022.01.007","article-title":"The hallmarks of cancer metabolism: still emerging","volume":"34","author":"Pavlova","year":"2022","journal-title":"Cell Metab"},{"key":"10.1016\/j.molmet.2025.102316_bib9","article-title":"Targeting Pyrimidine Metabolism in the Era of Precision Cancer Medicine","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.molmet.2025.102316_bib10","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20120097","article-title":"Dihydro-orotate dehydrogenase is physically associated with the respiratory complex and its loss leads to mitochondrial dysfunction","volume":"33","author":"Fang","year":"2013","journal-title":"Biosci Rep"},{"issue":"1","key":"10.1016\/j.molmet.2025.102316_bib11","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.freeradbiomed.2010.04.006","article-title":"Dihydroorotate dehydrogenase is required for N-(4-hydroxyphenyl)retinamide-induced reactive oxygen species production and apoptosis","volume":"49","author":"Hail","year":"2010","journal-title":"Free Radic Biol Med"},{"issue":"21","key":"10.1016\/j.molmet.2025.102316_bib12","doi-asserted-by":"crossref","first-page":"6685","DOI":"10.1182\/bloodadvances.2023010337","article-title":"DHODH: a promising target in the treatment of T-cell acute lymphoblastic leukemia","volume":"7","author":"Sexauer","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.molmet.2025.102316_bib13","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.87292","article-title":"DHODH inhibition enhances the efficacy of immune checkpoint blockade by increasing cancer cell antigen presentation","volume":"12","author":"Mullen","year":"2024","journal-title":"Elife"},{"issue":"10","key":"10.1016\/j.molmet.2025.102316_bib14","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1038\/s41375-019-0461-5","article-title":"The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignancies","volume":"33","author":"Christian","year":"2019","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.molmet.2025.102316_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/metabo14080413","article-title":"Metabolic Plasticity of Glioblastoma Cells in Response to DHODH Inhibitor BAY2402234 Treatment","volume":"14","author":"Bezawork-Geleta","year":"2024","journal-title":"Metabolites"},{"issue":"12","key":"10.1016\/j.molmet.2025.102316_bib16","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/j.ccell.2022.10.009","article-title":"Cancer-selective metabolic vulnerabilities in MYC-amplified medulloblastoma","volume":"40","author":"Gwynne","year":"2022","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.molmet.2025.102316_bib17","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1038\/s41467-023-38753-6","article-title":"Lysyl oxidase-like 3 restrains mitochondrial ferroptosis to promote liver cancer chemoresistance by stabilizing dihydroorotate dehydrogenase","volume":"14","author":"Zhan","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.molmet.2025.102316_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215981","article-title":"ENT1 blockade by CNX-774 overcomes resistance to DHODH inhibition in pancreatic cancer","volume":"552","author":"Mullen","year":"2023","journal-title":"Cancer Lett"},{"issue":"19","key":"10.1016\/j.molmet.2025.102316_bib19","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1038\/s41388-024-03005-4","article-title":"DHODH inhibition represents a therapeutic strategy and improves abiraterone treatment in castration-resistant prostate cancer","volume":"43","author":"Guo","year":"2024","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.molmet.2025.102316_bib20","doi-asserted-by":"crossref","first-page":"R165","DOI":"10.1530\/ERC-15-0137","article-title":"Regulation of tumor cell plasticity by the androgen receptor in prostate cancer","volume":"22","author":"Bishop","year":"2015","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"10.1016\/j.molmet.2025.102316_bib21","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1200\/JCO.1983.1.6.368","article-title":"Doxorubicin, Mitomycin-C, and 5-Fluorouracil (DMF) in the Treatment of Metastatic Hormonal Refractory Adenocarcinoma of the Prostate, With a Note on the Staging of Metastatic Prostate Cancer","volume":"1","author":"Logothetis","year":"1983","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.molmet.2025.102316_bib22","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1101\/gad.299958.117","article-title":"Nuclear mTOR acts as a transcriptional integrator of the androgen signaling pathway in prostate cancer","volume":"31","author":"Audet-Walsh","year":"2017","journal-title":"Genes Dev"},{"key":"10.1016\/j.molmet.2025.102316_bib23","first-page":"5563","article-title":"Activity of a novel 4-quinolinecarboxylic acid, NSC 368390 [6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinolinecarb oxylic acid sodium salt], against experimental tumors","volume":"45","author":"Dexter D","year":"1985","journal-title":"Cancer Res"},{"key":"10.1016\/j.molmet.2025.102316_bib24","first-page":"32","article-title":"Multicenter phase II study of brequinar sodium in patients with advanced lung cancer","author":"Maroun","year":"1993","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.molmet.2025.102316_bib25","doi-asserted-by":"crossref","DOI":"10.1097\/00000421-199312000-00014","article-title":"Multicenter phase II study of brequinar sodium in patients with advanced breast cancer","author":"Cody","year":"1993","journal-title":"Am J Clin Oncol"},{"issue":"6","key":"10.1016\/j.molmet.2025.102316_bib26","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1593\/neo.10168","article-title":"Teriflunomide (leflunomide) promotes cytostatic, antioxidant, and apoptotic effects in transformed prostate epithelial cells: evidence supporting a role for teriflunomide in prostate cancer chemoprevention","volume":"12","author":"Hail","year":"2010","journal-title":"Neoplasia"},{"issue":"9","key":"10.1016\/j.molmet.2025.102316_bib27","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.3324\/haematol.2019.230482","article-title":"ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia","volume":"105","author":"Zhou","year":"2020","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.molmet.2025.102316_bib28","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1535-7163.MCT-18-0863","article-title":"Targeting of Hematologic Malignancies with PTC299, A Novel Potent Inhibitor of Dihydroorotate Dehydrogenase with Favorable Pharmaceutical Properties","volume":"18","author":"Cao","year":"2019","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"10.1016\/j.molmet.2025.102316_bib29","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.ccell.2022.07.012","article-title":"A druggable addiction to de novo pyrimidine biosynthesis in diffuse midline glioma","volume":"40","author":"Pal","year":"2022","journal-title":"Cancer Cell"},{"issue":"269","key":"10.1016\/j.molmet.2025.102316_bib30","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"issue":"5","key":"10.1016\/j.molmet.2025.102316_bib31","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"issue":"5","key":"10.1016\/j.molmet.2025.102316_bib32","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ccr.2005.10.001","article-title":"Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression","volume":"8","author":"Varambally","year":"2005","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.molmet.2025.102316_bib33","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/pros.20961","article-title":"Optimizing molecular signatures for predicting prostate cancer recurrence","volume":"69","author":"Sun","year":"2009","journal-title":"Prostate"},{"issue":"1","key":"10.1016\/j.molmet.2025.102316_bib34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ccr.2010.05.026","article-title":"Integrative genomic profiling of human prostate cancer","volume":"18","author":"Taylor","year":"2010","journal-title":"Cancer Cell"},{"issue":"23","key":"10.1016\/j.molmet.2025.102316_bib35","doi-asserted-by":"crossref","first-page":"11428","DOI":"10.1073\/pnas.1902651116","article-title":"Genomic correlates of clinical outcome in advanced prostate cancer","volume":"116","author":"Abida","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.molmet.2025.102316_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2022.101516","article-title":"Multiple metabolic pathways fuel the truncated tricarboxylic acid cycle of the prostate to sustain constant citrate production and secretion","volume":"62","author":"Fregeau-Proulx","year":"2022","journal-title":"Mol Metab"},{"issue":"11","key":"10.1016\/j.molmet.2025.102316_bib37","doi-asserted-by":"crossref","DOI":"10.1172\/JCI170809","article-title":"The estrogen signaling pathway reprograms prostate cancer cell metabolism and supports proliferation and disease progression","volume":"134","author":"Lafront","year":"2024","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.molmet.2025.102316_bib38","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.cell.2018.03.059","article-title":"SnapShot: TCGA-analyzed tumors","volume":"173","author":"Blum","year":"2018","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.molmet.2025.102316_bib39","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","article-title":"The molecular taxonomy of primary prostate cancer","volume":"163","year":"2015","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.molmet.2025.102316_bib40","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1038\/s41467-019-09234-6","article-title":"Metascape provides a biologist-oriented resource for the analysis of systems-level datasets","volume":"10","author":"Zhou","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.molmet.2025.102316_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2019.04.016","article-title":"Functional genomic studies reveal the androgen receptor as a master regulator of cellular energy metabolism in prostate cancer","volume":"191","author":"Gonthier","year":"2019","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"7381","key":"10.1016\/j.molmet.2025.102316_bib42","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nature10642","article-title":"Reductive carboxylation supports growth in tumour cells with defective mitochondria","volume":"481","author":"Mullen","year":"2011","journal-title":"Nature"},{"issue":"23","key":"10.1016\/j.molmet.2025.102316_bib43","doi-asserted-by":"crossref","first-page":"4537","DOI":"10.1016\/j.molcel.2022.10.005","article-title":"Reversal of mitochondrial malate dehydrogenase 2 enables anaplerosis via redox rescue in respiration-deficient cells","volume":"82","author":"Altea-Manzano","year":"2022","journal-title":"Mol Cell"},{"issue":"6572","key":"10.1016\/j.molmet.2025.102316_bib44","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1126\/science.abi7495","article-title":"Fumarate is a terminal electron acceptor in the mammalian electron transport chain","volume":"374","author":"Spinelli","year":"2021","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.molmet.2025.102316_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2020.165759","article-title":"Dihydroorotate dehydrogenase in oxidative phosphorylation and cancer","volume":"1866","author":"Boukalova","year":"2020","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"7824","key":"10.1016\/j.molmet.2025.102316_bib46","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41586-020-2475-6","article-title":"Mitochondrial ubiquinol oxidation is necessary for tumour growth","volume":"585","author":"Martinez-Reyes","year":"2020","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.molmet.2025.102316_bib47","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.cmet.2018.10.014","article-title":"Reactivation of Dihydroorotate Dehydrogenase-Driven Pyrimidine Biosynthesis Restores Tumor Growth of Respiration-Deficient Cancer Cells","volume":"29","author":"Bajzikova","year":"2019","journal-title":"Cell Metab"},{"issue":"3","key":"10.1016\/j.molmet.2025.102316_bib48","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1079\/PNS2006498","article-title":"Glutamine in critical care: current evidence from systematic reviews","volume":"65","author":"Avenell","year":"2006","journal-title":"Proc Nutr Soc"},{"issue":"9","key":"10.1016\/j.molmet.2025.102316_bib49","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000769","article-title":"ASS1 inhibits liver cancer by promoting CAD ubiquitination and reversing the urea cycle and pyrimidine synthesis imbalance","volume":"9","author":"Ming","year":"2025","journal-title":"Hepatol Commun"},{"issue":"18","key":"10.1016\/j.molmet.2025.102316_bib50","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.1016\/j.molcel.2021.08.005","article-title":"The context-specific roles of urea cycle enzymes in tumorigenesis","volume":"81","author":"Hajaj","year":"2021","journal-title":"Mol Cell"},{"issue":"1","key":"10.1016\/j.molmet.2025.102316_bib51","doi-asserted-by":"crossref","first-page":"5355","DOI":"10.1038\/s41467-025-60204-7","article-title":"Iron deficiency causes aspartate-sensitive dysfunction in CD8(+) T cells","volume":"16","author":"Teh","year":"2025","journal-title":"Nat Commun"},{"issue":"13","key":"10.1016\/j.molmet.2025.102316_bib52","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1182\/blood.2024025245","article-title":"alpha-Ketoglutarate dehydrogenase is a therapeutic vulnerability in acute myeloid leukemia","volume":"145","author":"Millman","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.molmet.2025.102316_bib53","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.78654","article-title":"Mitochondrial redox adaptations enable alternative aspartate synthesis in SDH-deficient cells","volume":"12","author":"Hart","year":"2023","journal-title":"Elife"},{"issue":"4","key":"10.1016\/j.molmet.2025.102316_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111105","article-title":"Skeletal progenitors preserve proliferation and self-renewal upon inhibition of mitochondrial respiration by rerouting the TCA cycle","volume":"40","author":"Tournaire","year":"2022","journal-title":"Cell Rep"},{"issue":"10","key":"10.1016\/j.molmet.2025.102316_bib55","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/s41585-024-00899-3","article-title":"Rediscovering citrate as a biomarker for prostate cancer","volume":"21","author":"Galey","year":"2024","journal-title":"Nat Rev Urol"},{"issue":"5","key":"10.1016\/j.molmet.2025.102316_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.115596","article-title":"Combined inhibition of de novo glutathione and nucleotide biosynthesis is synthetically lethal in glioblastoma","volume":"44","author":"Udutha","year":"2025","journal-title":"Cell Rep"},{"issue":"3","key":"10.1016\/j.molmet.2025.102316_bib57","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1172\/JCI76029","article-title":"Coactivator SRC-2-dependent metabolic reprogramming mediates prostate cancer survival and metastasis","volume":"125","author":"Dasgupta","year":"2015","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.molmet.2025.102316_bib58","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1172\/JCI87800","article-title":"Glutaminase and poly(ADP-ribose) polymerase inhibitors suppress pyrimidine synthesis and VHL-deficient renal cancers","volume":"127","author":"Okazaki","year":"2017","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.molmet.2025.102316_bib59","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1158\/2159-8290.CD-16-0612","article-title":"PTEN Regulates Glutamine Flux to Pyrimidine Synthesis and Sensitivity to Dihydroorotate Dehydrogenase Inhibition","volume":"7","author":"Mathur","year":"2017","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.molmet.2025.102316_bib60","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ccell.2016.03.001","article-title":"N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells","volume":"29","author":"Lee","year":"2016","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.molmet.2025.102316_bib61","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41467-023-35802-y","article-title":"A CRISPR-Cas9 screen identifies EXO1 as a formaldehyde resistance gene","volume":"14","author":"Gao","year":"2023","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.molmet.2025.102316_bib62","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1002\/1878-0261.13441","article-title":"Isocitrate dehydrogenase 1 sustains a hybrid cytoplasmic-mitochondrial tricarboxylic acid cycle that can be targeted for therapeutic purposes in prostate cancer","volume":"17","author":"Gonthier","year":"2023","journal-title":"Mol Oncol"}],"container-title":["Molecular Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212877825002236?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212877825002236?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T23:24:02Z","timestamp":1775604242000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212877825002236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":62,"alternative-id":["S2212877825002236"],"URL":"https:\/\/doi.org\/10.1016\/j.molmet.2025.102316","relation":{},"ISSN":["2212-8778"],"issn-type":[{"value":"2212-8778","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting DHODH reveals a metabolic vulnerability in AR-positive and AR-negative prostate cancer cells via pyrimidine synthesis and metabolic crosstalk with the TCA and urea cycles","name":"articletitle","label":"Article Title"},{"value":"Molecular Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmet.2025.102316","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"102316"}}